Esketamine for depression: all studies (page 25)

Insomnia and Esketamine Add-On Therapy to Antidepressant Therapy in Patients with Treatment-Resistant Depression-A Pilot Study.

Pharmaceuticals July 19, 2025 Daniel Szawarnoga, Joanna Fojcik, Michał Górski et al. 1 citation

Background: Insomnia, as one of the most common sleep disorders, is a significant health problem, especially among patients suffering from drug-resistant depression. Problems related to the quality of sleep in that population can significantly affect the effectiveness of treatment and quality of life, which is why it is necessary to search for effective therapeutic interventions in this area....

DOI: 10.3390/ph18071066 Full text Esketamine Treatment-resistant depression S-ketamine Insomnia +5

Does BMI matter when treating depression with esketamine? A retrospective analysis of real-world data.

Journal of Affective Disorders July 15, 2025 Mina Ansari, Taeho Greg Rhee, Mia C Santucci et al. 4 citations

Intranasal (IN) esketamine was approved as a therapy for treatment-resistant depression in March 2019. There continues to be interest in the field to better understand factors associated with response to treatment. The aim of the current study is to assess the association between BMI and response to esketamine. A retrospective analysis was conducted on all patients treated with intranasal...

DOI: 10.1016/j.jad.2025.03.198 Full text Esketamine Treatment-resistant depression Psychiatric treatment Depression treatment +4

When mood and time align: nasal esketamine reduces lived time disturbances in treatment-resistant depression.

International Journal of Psychiatry in Clinical Practice July 10, 2025 Stefan Jerotić, Milica Nestorovic, Janko Nešić et al. 3 citations

These two cases highlight the utility of a focused, structured clinical phenomenological interview in measuring treatment effectiveness in subjective experience. Two male patients, aged 35 and 27, of Serbian ethnicity with treatment-resistant depression were treated with nasal esketamine, with clinical progress monitored using both the Montgomery-Åsberg Depression Rating Scale (MADRS) and the...

DOI: 10.1080/13651501.2025.2528692 Full text Esketamine Phenomenology Treatment-resistant depression Depression treatment +15

Antidepressant effects of esketamine are associated with functional connectivity in the hippocampal subregion: A resting state magnetic resonance study.

Neuroscience July 8, 2025 Xiang Liu, Yumeng Liu, Jun Tu et al. 2 citations

We aimed to investigate the relationship between changes in resting-state functional connectivity in a subregion of the hippocampus and the antidepressant effects of esketamine as well as to identify potential neuroimaging markers of the treatment outcomes. Twenty-nine patients with major depressive disorder (MDD) received six intravenous infusions of esketamine. All patients completed the...

DOI: 10.1016/j.neuroscience.2025.07.016 Full text Esketamine Major depressive disorder Mdd Functional connection +14

S-ketamine ameliorates post-stroke depression in mice via attenuation of neuroinflammation, synaptic restoration, and BDNF pathway activation.

Biochemical and Biophysical Research Communications July 8, 2025 Jiaxin Tian, Yanhong Xie, Sen Ye et al. 6 citations

The available therapeutic options for post-stroke depression patients are limited. Although SSRIs are the most commonly prescribed antidepressants, their slow onset of action and the higher risk of adverse effects or contraindications have led to an urgent need to develop fast-acting and highly specific antidepressants tailored to the needs of PSD patients. Therefore, ketamine has drawn...

DOI: 10.1016/j.bbrc.2025.151965 Full text S-ketamine Neuroinflammation Post-stroke depression psd Synaptic function +5

Esketamine disinhibits brain networks in depression: Evidence from oscillatory and aperiodic activity.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 5, 2025 Verina Guirguis, Sanvi Korsapathy, Francesca Pupillo et al. 6 citations

Nasal Esketamine is a rapid-acting intervention for depression, hypothesized to exert its effects through cortical disinhibition. However, the spatio-temporal dynamics of brain network activity and their relationship to the subjective drug experience following Esketamine administration remain elusive. This observational study aims to delineate brain network-level effects of Esketamine by...

DOI: 10.1016/j.pnpbp.2025.111438 Full text Major depressive disorder Aperiodic exponent Brain oscillations Esketamine treatment +9

Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment.

European Journal of Pharmacology July 5, 2025 Jolien K E Veraart, Sanne Y Smith-Apeldoorn, Jeanine Kamphuis et al. 2 citations

Oral esketamine has relatively low and variable bioavailability, which may complicate broader use as an antidepressant. This study aimed to investigate associations between different pharmacokinetic outcomes and change in depressive symptoms following oral esketamine administration in patients with treatment-resistant depression. Understanding such associations may inform dosing and...

DOI: 10.1016/j.ejphar.2025.177470 Full text Mdd Spravato Clinical depression Esketamine ketamine +5

Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial.

JAMA Psychiatry July 2, 2025 Adam Janik, Xin Qiu, Rosanne Lane et al. 40 citations

Esketamine nasal spray, administered in conjunction with an oral antidepressant, is approved for treatment-resistant depression (TRD). However, the efficacy of esketamine nasal spray administered as monotherapy for patients with TRD has not yet been evaluated. To assess the efficacy and safety of esketamine monotherapy compared to placebo in reducing depressive symptoms in patients with TRD....

DOI: 10.1001/jamapsychiatry.2025.1317 Full text Esketamine nasal spray Treatment-resistant depression Depression treatment Antidepressant therapy +35

Intranasal esketamine significantly alleviates depression severity and suicidal ideations in electroconvulsive therapy (ECT) non-responders.

European Archives of Psychiatry and Clinical Neuroscience July 1, 2025 Erhan Kavakbasi, Kevin Rosemann, Mert Yilmaz et al. 2 citations

Intranasal esketamine (ESK) is a novel therapy option in patients with treatment-resistant depression (TRD). Patients with a history of electroconvulsive therapy (ECT) non-response (ECT+) in the current episode have usually been excluded from previous studies. Data on the effectiveness of ESK in ECT non-responders are sparse. In this retrospective study, we investigated the effectiveness of...

DOI: 10.1007/s00406-025-02041-9 Full text Esketamine Major depressive disorder Electroconvulsive therapy Novel antidepressants +1

Efficacy of Intranasal Esketamine in Treatment-Resistant Depression: A Six-Month Real-World Follow-Up Study of Depressive Symptoms, Hopelessness, and Suicide Risk.

Human Psychopharmacology: Clinical and Experimental July 1, 2025 Maurizio Pompili, Maria Anna Trocchia, Ludovica Longhini et al. 3 citations

Treatment-resistant depression is one of the most significant clinical challenges in psychiatric practice. The primary aim of the present study was to assess the efficacy and tolerability of intranasal esketamine on depressive symptoms in a real-world outpatient setting. A secondary objective was to explore the potential benefits of intranasal esketamine on hopelessness and suicide risk...

DOI: 10.1002/hup.70008 Full text Esketamine Treatment-resistant depression Suicide prevention Suicide risk +2